Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation

Microsurgery

Volumn 19, Issue 2, 1999, Pages 98-102

  Antoniou, Efstathios A ^a,d   Deroover, Arnaud ^a   Howie, Alexander J ^b   Chondros, Kostas ^c   Mcmaster, Paul ^a   D'Silva, Milbhor ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF ATHENS   (Greece)

^d Transplant Microsurgery Laboratory   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREQUINAR; LEFLUNOMIDE; TACROLIMUS;

ALLOTRANSPLANTATION; ANIMAL MODEL; ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIPHENYL COMPOUNDS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; POSTOPERATIVE PERIOD; RATS; RATS, INBRED LEW; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 0033009023     PISSN: 07381085     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2752(1999)19:2<98::AID-MICR11>3.0.CO;2-C     Document Type: Article

References (15)

1. Cramer DV, Chapman FA, Makowka L. Prevention of vascularized allograft and xenogratt rejection in rodents by brequinar sodium. Transplant Proc 1993;25:2:23-28.
2. Chen SF, Ruben RL, Dexter DL. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-I,I′-biphenyl-4-YL)-3-methyly-4- quinolinecarboxylic acid sodium-salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 1986;46: 5014-5019.
3. Allison AC, Eugi EM. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc 1993;25:8-18.
4. Makowka L, Chapman FA, Cramer DV. Historical development of brequinar sodium as a new immunosuppressive. Transplant Proc 1993; 25:2-7.
5. Cramer DV, Chapman FA, Jaffee BD, et al. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection. Transplantation 1992;53:303-308.
6. Cosenza CA, Cramer DV, Hrehhaeiras G, Cajulis E, Wang HK, Makowka L. Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection. Transplant Proc 1993;25:57-58.
7. Rozman B, Mladenovic V, Domljan Z, et al. The effects of leflunomide (LF) in patients with rheumatoid arthritis (RA). Arthritis Rheumatism 1992;35(suppl):S108.
8. Schorlemmer HU, Seiler FR, Bartlett RR. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant Proc 1993; 25:763-767.
9. Williams JW, Xiao F, Foster PF, et al. Immunosuppressive effects of leflunomide in a cardiac allograft model. Transplant Proc 1993;25: 745-746.
10. D'Silva M, Candinas D, Achilleos O, et al. The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation 1995;60:430-437.
11. D'Silva M, Antoniou EA, DeRoover A, Nishimura Y, Howie A, Mc-Master P. Immunosuppressive effect of Brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. Transplant Proc 1996;28:950-951.
12. Ono K, Lindsey ES. Improved techniques of heart transplant in rats. J Thoracic Cardiovasc Surg 1969;57:225.
13. Morrisey PE, Gollin G, Brusett K, Marks WH. Prolongation of allograft survival in rat heterotopic heart transplantation by TLCK, a serine protease inhibitor. Transplantation 1994;57:631-633.
14. Bruggeman CA, Debie WM, Grauls G, Majoor G, van Bowen CP. Infection in laboratory rats with a new cytomegalo-like virus. Arch Virol 1983;76:189-199.
15. Stals FS, Bosman F, van Bowen CP, Bruggeman CA. An animal model for therapeutic intervention studies of CMV infection in the immunocompromised host. Arch Virol 1990;114:91107.